Two real-world studies indicated that IL-5 antagonists were effective in reducing oral corticosteroids and improving respiratory function in patients with coexistent bronchiectasis and severe eosinophilic asthma [38, 39]. The gene discussed is IL5; the disease is bronchiectasis.